Overall, 26 patients (68.4%) received treatment for t-MDS, including recombinant erythropoietin in 14 patients (36.8%), hypomethylating agents (HMA) in 8 patients (21.1%), eltrombopag in two patients (5.3%), luspatercept and lenalidomide in one patient each. Here, EPO is linked to myelodysplastic syndrome.